Abnormal function of the vasopressin-cyclic-AMP-aquaporin2 axis during urine concentrating and diluting in patients with reduced renal function. A case control study

Erling B Pedersen, Ingrid M Thomsen, Thomas G Lauridsen, Erling B Pedersen, Ingrid M Thomsen, Thomas G Lauridsen

Abstract

Background: The kidneys ability to concentrate and dilute urine is deteriorated during progressive renal insufficiency. We wanted to test the hypothesis that these phenomena could be attributed to an abnormal function of the principal cells in the distal part of the nephron.

Methods: Healthy control subjects and patients with chronic kidney diseases were studied. Group 1 comprised healthy subjects, n = 10. Groups 2-4 comprised patients with chronic kidney disease (Group 2, n = 14, e-GFR ≤ 90 m1/min; Group 3, n = 11, 60 m1/min ≤ e-GFR < 90 ml/min; and Group 4, n = 16, 15 ml/min ≤ e-GFR < 60 ml/min). The subjects collected urine during 24 hours. A urine concentrating test was done by thirsting during the following 12 hours. Thereafter, a urine diluting test was performed with a water load of 20 ml/kg body weight. The effect variables were urinary excretions of aquaporin2 (u-AQP2), cyclic-AMP (u-c-AMP), urine volume (UV), free water clearance (CH2O), urine osmolarity (u-Osm), and plasma arginine vasopressin (p-AVP).

Results: After fluid deprivation, u-Osm increased. In all groups, UV and CH2O decreased and u-AQP2 and u-c-AMP increased in Groups 1 and 2, but were unchanged in Group 3 and 4. P-AVP was significantly higher in Group 4 than in the other groups. During urine diluting, UV and CH2O reached significantly higher levels in Groups 1-3 than Group 4. Both before and after water loading, u-AQP2 and p-AVP were significantly higher and u-c-AMP was significantly lower in Group 4 than the other groups. Estimated-GFR was correlated negatively to p-AVP and positively to u-c-AMP.

Conclusions: Patients with moderately severe chronic kidney disease have a reduced renal concentrating and diluting capacity compared to both patients with milder chronic kidney disease and healthy control subjects. These phenomena can be attributed, at least partly, to an abnormally decreased response in the AVP-c-AMP-AQP2 axis.ClinicalTrials.Gov Identifier: NCT00313430.

References

    1. Kwon TH, Hager H, Nejsum LN, Andersen ML, Frøkiaer J, Nielsen S. Physiology and pathophysiology of renal aquaporins. Semin Nephrol. 2001;21:231–238. doi: 10.1053/snep.2001.21647.
    1. Nielsen S, Frokiaer J, Marples D, Kwon TH, Agre P, Knepper MA. Aquaporins in the kidney: from molecules to medicine. Physiol Rev. 2002;82:205–244.
    1. Schrier RW. Molecular mechanisms of clinical concentrating and diluting disorders. Prog Brain Res. 2008;170:539–550. full_text.
    1. Chen YC, Cadnapaphornchai MA, Yang J, Summer SN, Falk S, Li C, Wang W, Schrier RW. Nonosmotic release of vasopressin and renal aquaporins in impaired urinary dilution in hypothyroidism. Am J Physiol Renal Physiol. 2005;289:F672–678. doi: 10.1152/ajprenal.00384.2004.
    1. Chen YC, Cadnapaphornchai MA, Summer SN, Falk S, Li C, Wang W, Schrier RW. Molecular mechanisms of impaired urinary concentrating ability in glucocorticoid-deficient rats. J Am Soc Nephrol. 2005;16:2864–2871. doi: 10.1681/ASN.2004110944.
    1. Wang W, Li C, Summer SN, Falk S, Cadnapaphornchai MA, Chen YC, Schrier RW. Molecular analysis of impaired urinary diluting capacity in glucocorticoid deficiency. Am J Physiol Renal Physiol. 2006;290:F1135–1142. doi: 10.1152/ajprenal.00356.2005.
    1. Wang W, Li C, Summer SN, Falk S, Schrier RW. Polyuria of thyrotoxicosis: downregulation of aquaporin water channels and increased solute excretion. Kidney Int. 2007;72:1088–1094. doi: 10.1038/sj.ki.5002475.
    1. Li C, Wang W, Summer SN, Falk S, Schrier RW. Downregulation of UT-A1/UT-A3 is associated with urinary concentrating defect in glucocorticoid-excess state. J Am Soc Nephrol. 2008;19:1975–1981. doi: 10.1681/ASN.2008010051.
    1. Verkman AS. Renal concentrating and diluting function in deficiency of specific aquaporin genes. Exp Nephrol. 2002;10:235–240. doi: 10.1159/000063697.
    1. Rojek A, Füchtbauer EM, Kwon TH, Frøkiaer J, Nielsen S. Severe urinary concentrating defect in renal collecting duct-selective AQP2 conditional-knockout mice. Proc Natl Acad Sci USA. 2006;103:6037–6042. doi: 10.1073/pnas.0511324103.
    1. Zhao D, Bankir L, Qian L, Yang D, Yang B. Urea and urine concentrating ability in mice lacking AQP1 and AQP3. Am J Physiol Renal Physiol. 2006;29:F429–438. doi: 10.1152/ajprenal.00011.2006.
    1. Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J, De Zeeuw D, Hostetter TH, Lameire N, Eknoyan G. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO) Kidney Int. 2005;67:2089–2100. doi: 10.1111/j.1523-1755.2005.00365.x.
    1. Pedersen RS, Bentzen H, Bech JN, Pedersen EB. Effect of water deprivation and hypertonic saline infusion on urinary AQP2 excretion in healthy humans. Am J Physiol Renal Physiol. 2001;280:F860–F867.
    1. Pedersen EB, Eiskjaer H, Madsen B, Danielsen H, Egeblad M, Nielsen CB. Effect of captopril on renal extraction of renin, angiotensin II, atrial natriuretic peptide and vasopressin, and renal vein renin ratio in patients with arterial hypertension and unilateral renal artery disease. Nephrol Dial Transplant. 1993;8:1064–1070.
    1. Hull JH, Halk LJ, Koch GG, Wargin WA, Chi SL, Mattocks AM. Influence of range of renal function and liver disease on predictability of creatinine clearance. Clin Pharmacol Ther. 1981;29:516–521. doi: 10.1038/clpt.1981.72.
    1. Pedersen RS, Bentzen H, Bech JN, Nyvad O, Pedersen EB. Urinary aquaporin-2 in healthy humans and patients with liver cirrhosis and chronic heart failure during baseline conditions and after acute water load. Kidney Int. 2003;63:1417–1425. doi: 10.1046/j.1523-1755.2003.00858.x.
    1. Starklint J, Bech JN, Pedersen EB. Down-regulation of urinary AQP2 and unaffected response to hypertonic saline after 24 hours of fasting in humans. Kidney Int. 2005;67:1010–1018. doi: 10.1111/j.1523-1755.2005.00164.x.
    1. Halperin ML, Kamel KS, Oh MS. Mechanisms to concentrate the urine: an opinion. Curr Opin Nephrol Hypertens. 2008;17:416–422. doi: 10.1097/MNH.0b013e328304b3f5.
    1. Sands JM, Layton HE. The physiology of urinary concentration: an update. Semin Nephrol. 2009;29:178–195. doi: 10.1016/j.semnephrol.2009.03.008.
    1. Nakamura T, Saito T, Kusaka I, Higashiyama M, Nagasaka S, Ishibashi S, Ishikawa SE. Decrease in urinary excretion of aquaporin-2 associated with impaired urinary concentrating ability in diabetic nephropathy. Nephron. 2002;92:445–448. doi: 10.1159/000063285.
    1. Davis BB, Zenser TV. Evaluation of renal concentrating and diluting ability. Clin Lab Med. 1993;13:131–134.
    1. Zahran A, Mabood Qureshi M, Shoker. A Comparison between creatinine and cystatin C-based GFR equations in renal transplantation. Nephrol Dial Transplant. 2007;22:2659–2668. doi: 10.1093/ndt/gfm243.
    1. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31–41. doi: 10.1159/000180580.
    1. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130:461–470.
    1. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604–612.
    1. Sands JM. Urinary concentration and dilution in the aging kidney. Semin Nephrol. 2009;29:579–586. doi: 10.1016/j.semnephrol.2009.07.004.
    1. Tian Y, Serino R, Verbalis JG. Downregulation of renal vasopressin V2 receptor and aquaporin-2 expression parallels age-associated defects in urine concentration. Am J Physiol Renal Physiol. 2004;287:F797–805. doi: 10.1152/ajprenal.00403.2003.
    1. Wong NL, Tsui JK. Angiotensin II upregulates the expression of vasopressin V2 mRNA in the inner medullary collecting duct of the rat. Metabolism. 2003;52:290–295. doi: 10.1053/meta.2003.50047.
    1. Kwon TH, Nielsen J, Knepper MA, Frokiaer J, Nielsen S. Angiotensin II AT1 receptor blockade decreases vasopressin-induced water reabsorption and AQP2 levels in NaCl-restricted rats. Am J Physiol Renal Physiol. 2005;288:F673–F684. doi: 10.1152/ajprenal.00304.2004.
    1. Lee J, Yoo K, Kim SW, Jung KH, Ma SK, Lee YK, Kim WY, Kim J, Choi KC. Decreased expression of aquaporin water channels in denervated rat kidney. Nephron Physiol. 2006;103:170–178. doi: 10.1159/000092918.
    1. Lee YJ, Song IK, Jang KJ, Nielsen J, Frøkiaer J, Nielsen S, Kwon TH. Increased AQP2 targeting in primary cultured IMCD cells in response to angiotensin II through AT1 receptor. Am J Physiol Renal Physiol. 2007;292:F340–F350. doi: 10.1152/ajprenal.00090.2006.
    1. de Seigneux S, Nielsen J, Olesen ET, Dimke H, Kwon TH, Frøkiaer J, Nielsen S. Long-term aldosterone treatment induces decreased apical but increased basolateral expression of AQP2 in CCD of rat kidney. Am J Physiol Renal Physiol. 2007;293:F87–F99. doi: 10.1152/ajprenal.00431.2006.
    1. Wang X, Wu Y, Ward CJ, Harris PC, Torres VE. Vasopressin directly regulates cyst growth in polycystic kidney disease. J Am Soc Nephrol. 2008;19:102–108. doi: 10.1681/ASN.2007060688.
    1. Torres VE. Role of vasopressin antagonists. Clin J Am Soc Nephrol. 2008;4:1212–1218. doi: 10.2215/CJN.05281107.
    1. Belibi FA, Edelstein CL. Novel targets for the treatment of autosomal dominant polycystic kidney disease. Expert Opin Investig Drugs. 2010;19:315–328. doi: 10.1517/13543781003588491.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit